Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Tue 28 Nov 2006, 7:19 Sekunjalo Investments Limited - Press Release
SKJ
 SKJ                                                                             
Sekunjalo Investments Limited - Press Release                                   
Sekunjalo Investments Limited                                                   
Share code: SKJ                                                                 
ISIN: ZAE000017893                                                              
Press Release                                                                   
Date: 28 November 2006                                                          
Headline Earnings and Operating Profits rocket for Sekunjalo as Technology and  
Innovation Driven Investments pay off                                           
(Full results and commentary live on SENS)                                      
JSE-listed Sekunjalo Investments Limited today announced a 644% increase in     
headline earnings (R67,3 m), a 101% increase in operating profits (R92 m) and a 
602% increase in headline earnings per share (21 cents) for the 12 months ended 
31 August 2006, as the company"s diversification into Technology and Innovation 
Driven Sectors delivered excellent results.                                     
The technology and innovation driven investments include the ICT investments    
(Business Intelligence, Financial Management and Hospital Information Systems   
software companies); Aquaculture (abalone), Biotechnology (Bioclones) and       
Financial Services (locally and internationally).                               
"This is the second consecutive year in which Sekunjalo"s headline earnings are 
in excess of 300%.  Sekunjalo has not only delivered in terms of its Broad Based
Empowerment status (being named the Top BEE company for 2006 by Financial Mail  
and Empowerdex) it has also performed strongly, financially,"  said Dr Iqbal    
Surve, Chairman and CEO.                                                        
"I am confident that the consistent growth in profitability will be recognised  
by the investment community so that the gap between the increasing share price  
and Company NAV of R2,51 per share is narrowed."                                
Sekunjalo Investments Limited is rapidly gaining in stature as a successful,    
diversified, financially driven Group, with an aggressive strategy to achieve   
growth in the value of investments. As a result, the NAV of the Company has     
increased to R903,5 million against a value of R813,8 million (2005).           
"This strong increase in NAV clearly reflects the company"s ability to identify,
acquire and grow suitable investments in line with its investment strategy."    
"The Group continues to be lowly geared and financially strong, with a debt to  
equity ratio of 14%.  Sekunjalo has a global business presence with             
representation in 3 countries, namely South Africa, Mauritius (headed by Raj    
Gopaul), and the UK (headed by John Whatley). The appointment to the Board of   
Mihe Goamab, The First, has given the Group an important entry into the SADC    
countries of Namibia, Botswana and Angola," Dr Surve said.                      
Norman Noland, Deputy CEO, said, "The strategic shift made two years ago to     
diversify into Technology and Innovation Driven Investments has been rapid and  
successful. Our strategic shift was made to lessen reliance on the historical   
investments in resource driven sectors such as fishing, as well as health care, 
which by nature is seasonally volatile. The decision was further influenced by  
the opportunities in Technology Driven Businesses which continually became      
available as a result of Sekunjalo"s status as a leading empowerment company."  
"Simultaneous with the speedy implementation of the diversification strategy the
Group has implemented a financially driven model encompassing structure, system 
and processes and resources thus creating a successful platform for growth.     
Executives, rich in experience and intellectual capital have been appointed at  
corporate office and divisional level. The decision to build a disciplined      
conglomerate is definitely succeeding."                                         
Norman Noland said, "The hard work by a committed team over the last 2 years is 
reaping rewards, Our ICT, financial services, aquaculture and biotechnology     
operations were star performers.  The biggest contributor to the increase at    
operating profit level came from the Technology and Innovation Driven           
Investments whilst the Group"s plans for fixing, consolidating and growing      
historical investments shows strong signs of beginning to work.                 
"The Technology Driven Investments excluding the fair value of Bioclones        
generated an operating profit of R 40 million," Noland said.                    
The company"s ICT interests housed in Sekunjalo Informatics and                 
Telecommunications Africa (SITCA) had exceeded expectations, positioning SITCA  
for a proposed listing on the JSE.  The four main operating ICT companies -     
Synergy, FIOS, HST and Saratoga performed well. He singled out FIOS for special 
commendation.                                                                   
"FIOS is clearly carving out a "Market Leader Status" in its field and continues
to be sought out by the South African blue chips.  The financial management     
software company has delivered profits significantly ahead of those anticipated 
and was recently successfully awarded a project with one of the country"s major 
banks," Noland said.                                                            
Alongside SITCA, the Group"s Financial Services Division, Sekunjalo Capital, has
again produced excellent results.  Noland said this is likely to continue as a  
large share of the revenue is annuity derived.                                  
The Group"s aquaculture division, consisting primarily of its Gansbaai abalone  
farm, had an excellent year, validating the decision to expand in this sector.  
Revenue is up and prospects are strong, based on the relative maturity (larger  
organism asset base) of this operation which allows  it to bring four and five  
year old abalone to market.  Future prospects are promising as South African    
abalone continues to be highly prized abroad.                                   
Manufacturing and Resource Based investments: Premier Fishing managed to hold   
its own despite difficult fishing conditions and a once off non-recurring loss  
in an international trading joint venture.  Healthcare, as planned, had a       
successful turnaround in the second half of the financial year. Both Premier    
Fishing,  because of its very successful long term lobster rights allocation and
Health Care, due to its JV"s with multinationals - are expected to contribute   
significantly in the coming financial year.                                     
This financial year has been one of building and cementing significant          
partnerships with multinationals. In Pharmaceuticals JV"s have been developed   
with Indian based Unichem and Orchid Pharma and UAE based Julphar.  In ICT-     
Health Care; IT- Siemens; BI - Cognos and Microsoft.  In Biotechnology with     
Swiss based Solidago AG. These partnerships are expected to contribute          
significantly to the profits of the group in the years ahead.                   
Commenting on the prospects for the Group, Norman Noland said they are excellent
based on the growth of the Technology and Innovation Driven Investments.        
Sekunjalo"s Business Intelligence (BI), financial consolidation and hospital    
information software companies, currently used by 350 blue-chip clients, have   
opportunities to expand into Government and the private and public sector.      
Premier Fishing has been allocated one of the largest allocations in lobster in 
the southern hemisphere, and its lobster is a preferred brand in export markets,
including the USA.  In Biotechnology, Bioclones has two products licensed for   
expansion into the global market- EPO (Repotin) into a US $12 billion market and
G-CSF (with a recent SA Government investment of US$ 5,3 million) into a US $ 3 
billion market. Further products of the 22 global patents held by Bioclones are 
being evaluated for commercialisation.                                          
Norman Noland expressed his excitement and confidence about the future of the   
Group and said that Sekunjalo will be making significant announcements in the   
first quarter of 2007, two of which relate to its Technology and Innovation     
Driven businesses.                                                              
Ends - contact numbers follow                                                   
Prepared by:        Bruce Hetherington                                          
               Beachhead Media & Investor Relations                             
               082 458 2199                                                     
Contact details:         Sekunjalo Investments Limited                          
                    Zenariah Barends                                            
                    Mobile: 082 441 0433                                        
                    Dr Iqbal Surve (Chairman and CEO)                           
Mobile: 082 491 0179                                        
                    Norman Noland (Deputy CEO)                                  
                    Mobile: 083 626 4135                                        
Date: 28/11/2006 07:19:59 AM Produced by the JSE SENS Department                
                                                                                
                                                                                
                                                                                
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
[  Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: